[1]王述文,姚红霞,饶 若.CD133-2在急性白血病病程中的表达及意义[J].现代检验医学杂志,2018,33(02):35-37.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　WANG Shu-wen,YAO Hong-xia,RAO Ruo.Expression of CD133-2 during the Courses of Acute Leukemia and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(02):35-37.[doi:10.3969/j.issn.1671-7414.2018.02.001]
点击复制

CD133-2在急性白血病病程中的表达及意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年02期
页码:
35-37
栏目:
论著
出版日期:
2018-04-05

文章信息/Info

Title:
Expression of CD133-2 during the Courses of Acute Leukemia and Its Clinical Significance
文章编号:
1671-7414(2018)02-035-03
作者:
王述文; 姚红霞; 饶 若
海南省人民医院血液病研究室,海口 570311
Author(s):
WANG Shu-wen; YAO Hong-xia; RAO Ruo
Hematologic Laboratory,Hainan General Hospital,Haikou 570311,China
关键词:
CD133-2;  急性白血病;  流式细胞术
分类号:
R557; R392.11
DOI:
10.3969/j.issn.1671-7414.2018.02.001
文献标志码:
A
摘要:
目的 探讨CD133-2在急性白血病病程中的表达及其临床意义。方法 通过直接免疫荧光流式细胞术对67例不同病程急性白血病(AL)进行CD133-2的检测。结果 AL组CD133-2的阳性率(52.4%)及表达率(23.9%±21.5%)均明显高于对照组(0,2.2%±3.9%); 初治组、完全缓解期(CR)组及复发组CD133-2的阳性率分别为52.4%,0和40.0%,表达率分别为23.9%±21.5%,5.0%±6.0%和28.4%±25.6%,三组间的阳性率及表达率差异有统计学意义(χ2=12.777,F=5.906,P<0.05)。初治组及复发组的CD133-2阳性率及表达率均明显高于CR组。初治患者CD34+组的CD133-2阳性表达率明显高于CD34-组(40.5% vs 7.1%,χ2=8.636,P<0.05),并且CD133-2-/CD34-组的CR率则明显高于CD133-2+/CD34+组(83.3% vs 33.3%,χ2=6.078,P<0.05)。结论 初治AL患者CD133表达与CD34相关; CD133/CD34共同高表达可能是AL的一个不良预后因素; 检测AL患者骨髓中CD133-2的表达可以作为预测复发及监测MRD的指标之一。
Abstract:
Abstract:Objective To explore the expression of CD133-2during the treatment course of acute leukemia(AL)and its clinical significance.Methods Used flow cytometry with direct immunofluorescence staining to analyze CD133-2 of 67 acute leukemia patients with different treatment courese.Results The CD133-2 positive rate(52.4%)and expression rate(23.9%±21.5%)in AL were significantly higher than those in control(0,2.2%±3.9%).The CD133-2 positive rates of cases for primary treatment group,CR group and recurrence group were 52.4%,0 and 40.0% respectively,and expression rates were 23.9%±21.5%,5.0%±6.0% and 28.4%±25.6% respectively.There were significant difference in the positive rate and expression rate of CD133-2 among the three group(χ2=12.777,F=5.906,P<0.05).The CD133-2 positive rates and expression rates in primary treatment group and recurrence group were significantly higher than those in complete remission cases.CD133-2 positive rate of CD34+ group was obviously higher than that of CD34-group(40.5% vs 7.1%,χ2=8.636,P<0.05),and the CR rate of CD133-2-/CD34- group was significantly higher than that of CD133-2+/CD34+ group(83.3% vs 33.3%,χ2=6.078,P<0.05).Conclusion The expression of CD133-2 was correlated with CD34,and CD133/CD34 co-overexpression might be a bad prognostic factor of AL.CD133-2 can be used as one of the indicator of predicting recurrence and monitoring MRD.

参考文献/References:

[1] Miraglia S,Godfrey W,Yin AH,et al.A novel five-transmembranehematopoietic stem cell antigen:isolation,characterization,and molecular cloning[J].Blood,1997,90(12):5013-5021.
[2] Green CL,Loken MR,Buck D,et al.Discordant expression of AC133 and AC141 inpatients with myelodysplastic syndrome and acute myelogenous leukemia[J].Leukemia,2000,14(4):770-772.
[3] 张之南,沈 悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:103-134. Zhang ZN,Shen T.Diagnostic and therapeutic criteria for hematological diseases[M].Beijing:Sciense Publishing House,2007:103-134.
[4] Yin AH,Miraglia S,Zanjani ED,et al.A novel marker for human hematopietic stem and progenitor cells[J].Blood,1997,90(12):5002-5012.
[5] 汪家敏,戴 兰,张光波,等.CD133-2分子在急性白血病患者骨髓单个核细胞中的表达及其临床意义[J].现代免疫学,2010,30(4):333-336. Wang JM,Dai L,Zhang GB,et al.Expression of C D133-2 molecule onbone marrow mononucleated cells of acute leukemia patients and its clinical significance[J].Current Immunology,2010,30(4):333-336.
[6] 赵文理,聂述山,许云云,等.CD133两种亚型分子在儿童B系急性淋巴细胞白血病中的表达及其临床意义[J].中国实验血液学杂志,2012,20(3):536-540. Zhao WL,Ne SS,Xu YY,et al.Expression of two subtype molecules ofCD133 in childhood with B linage acute lymphoblastic leukemia and its clinicalsignificance[J].Journal of Experimental Hematology,2012,20(3):536-540.
[7] Lee ST,Jang JH,Min YH,et al.AC133 antigen as a prognostic factor in acute leukemia[J].Leuk Res,2001,25(7):757-767.
[8] Lai C,Karp JE,Hourigan CS,et al.Precision medicine for acute myeloidleukemia[J].Expert Review of Hematology,2016,9(1):1-3.
[9] Jaso JM,Wang SA,Jorgensen JL,et al.Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML:pset,present andfuture[J].Bone Marrow Transplantation,2014,49(9):112-1138.
[10] 魏 佳,李惠民.多参数流式细胞术在检测急性髓系白血病微小残留病灶中的运用[J].重庆医学,2015,44(26):3712-3713,3737. Wei J,Li HM.Application of multi-parameter flow cytometry in detection of minimal residual lesions in acute myeloid leukemia[J].Chongqing Medicine,2015,44(26):3712-3713,3737

备注/Memo

备注/Memo:
作者简介:王述文(1979-),男,大学本科,主管技师,主要从事血液学检验,E-mail:9806034@163.com。
更新日期/Last Update: 2018-04-16